Real-world duration of maintenance therapy in 2nd-line and later ovarian cancer (OC)
| العنوان: | Real-world duration of maintenance therapy in 2nd-line and later ovarian cancer (OC) |
|---|---|
| المؤلفون: | Monica Labrador, Jeffrey A. Scott, David Garofalo, Joseph Donaldson, Jennifer Webster, Prateesh Varughese, Melissa Hagan, Ebru Aydin, Helen Smith, Ash Malik |
| المصدر: | Journal of Clinical Oncology. 37:e17103-e17103 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Maintenance therapy, business.industry, Duration (music), Internal medicine, medicine, Line (text file), Ovarian cancer, medicine.disease, business |
| الوصف: | e17103 Background: Recurrent OC patients may benefit from maintenance therapy, with the goal of inducing a lasting remission or extending the time interval before progression without any deleterious impact on quality of life1. This analysis, based on real world data sourced from US community oncology practices, was designed to compare the time to next treatment of available maintenance treatment options in recurrent OC. Methods: This analysis utilized the Integra Data Exchange (DTX) database, a deidentified data source from community oncology practice systems (EMR, claims). This retrospective study included 3,629 OC patients with at least two visits between 7/16/16 and 4/16/18. 1,767 patients started at least one 2nd line or later line of therapy and 577 of these patients had at least one line of maintenance treatment. Maintenance options were monotherapy PARP inhibitors, Bevacizumab, or non-platinum-chemotherapy. Patients who did not receive maintenance were categorized as observation. Time to next treatment (start of maintenance to start of next line of therapy) was compared through ANOVA and paired T-test analyses. Results: A statistically significant difference was seen in time to next treatment between PARPi (n = 151) and bevacizumab maintenance (n = 212) (p = < 0.0125) and between PARPi and cytotoxic maintenance (n = 163) (p = < 0.0001). Bevacizumab and PARPi maintenance had significantly longer duration when compared to observation (n = 1,626) (p = < 0.0001). Cytotoxic maintenance duration was not significantly different than observation (p = 0.93). Conclusions: Our real world analysis found that there was a statistically significant increase in time to subsequent lines of therapy when certain maintenance treatment (PARPi, Bevacizumab) is utilized following 2nd line and later treatment in OC. Further, between available maintenance options, PARPi had the longest time to next treatment when compared to other maintenance options.[Table: see text] |
| تدمد: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2019.37.15_suppl.e17103 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::8645d507e87ac14eabd9634c60df4ca3 https://doi.org/10.1200/jco.2019.37.15_suppl.e17103 |
| رقم الانضمام: | edsair.doi...........8645d507e87ac14eabd9634c60df4ca3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|---|
| DOI: | 10.1200/jco.2019.37.15_suppl.e17103 |